12:00 AM
 | 
Dec 16, 2002
 |  BioCentury  |  Emerging Company Profile

Neuro3d: Expertise over platform

Neuro3d SA has no particular drug discovery platform. But the company believes it will succeed because of its scientific and clinical expertise in neurobiological indications. The company has in-licensed a Phase I anti-psychotic compound from Johnson & Johnson and is starting preclinical studies after developing its own compounds against a target in-licensed from the University of Strasbourg.

Neuro3d's areas of expertise include schizophrenia, depression, anxiety and sleep disorders, CEO Charles Woler told BioCentury. As neurobiology remains one of the least understood fields of research, the company believes its collective scientific and clinical knowledge provides it with a concrete advantage in deriving therapeutic value from targets and compounds.

The company is applying its expertise via a three-pronged strategy, which includes in-licensing compounds, in-licensing targets, and using in-house medicinal chemistry...

Read the full 626 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >